Sep 22, 2026 · 6 min
Alibaba’s AI push meets rallies in apparel and biotech
Alibaba and ON Rise; Viking Therapeutics Surges
The episode shows how technology investment, consumer-brand expansion, and drug-development data are moving distinct parts of the market.
- 1Alibaba’s new AI chip and larger-model plans underscore its ambition to expand data-center capacity.
- 2On Holding’s expected high-teens sales growth reflects expansion beyond running into golf and football.
- 3Viking Therapeutics surged after data suggested less frequent dosing could preserve most weight loss after GLP-1 treatment.
Don't miss
Viking Therapeutics’ sharp premarket gain follows data suggesting less frequent dosing could preserve most weight loss after GLP-1 treatment.
The brief
Alibaba shares rose after the company unveiled a new AI chip, outlined larger-model plans, and signaled ambitions to expand data-center capacity.
The discussion places Alibaba’s technology in a broader U.S.-China context, while briefly examining the growing use of “agentic AI” in consumer products.
On Holding gained on expectations for high-teens sales growth as the sportswear company expands into golf and football; its ownership includes Roger Federer.
Viking Therapeutics surged after results suggested its experimental obesity drug could maintain most weight loss with less frequent dosing after GLP-1 treatment.
Together, the moves show investors responding to different kinds of evidence: infrastructure plans, growth expectations, and clinical data.
What was said on this episode
4 statements · 4 positive
On Holding expects sales growth in the high teens over the next few years.
“It expects sales growth in the high teens over the next few years.”
Listen at 2:10
On Holding is trying to take market share from Adidas and Nike.
“take market share away from Adidas or Adidas in Germany and Nike”
Listen at 2:17
Viking Therapeutics’ drug produced 22% weight loss over 33 weeks in a maintenance study.
“this drug led to a 22% weight loss over 33 weeks in what they call a maintenance study”
Listen at 3:17
Viking Therapeutics’ drug could compete with Eli Lilly and Novo Nordisk.
“it could be a contender to Eli Lilly and Novo Nordisk”
Listen at 3:24
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.